Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, BenzingaRatingsTable reports. They currently have a $25.00 target price on the stock, down from their previous target price of $28.00. HC Wainwright’s price objective would indicate a potential upside of 250.14% from the stock’s previous close.
Separately, ValuEngine raised shares of Bio-Path from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th.
Shares of BPTH opened at $7.14 on Monday. The firm has a market cap of $20.91 million, a P/E ratio of -0.50 and a beta of 3.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.85 and a quick ratio of 13.85. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52. The company has a 50 day simple moving average of $10.17 and a two-hundred day simple moving average of $11.98.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Article: Diversification in Investing
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.